Small Molecule Drugs
Small molecules are low‑molecular‑weight drugs that modulate discrete biological targets to treat infection, inflammation, coagulopathy, pain and metabolic dysregulation in combat- and austere-care settings. Their chemical stability, scalable manufacture, and multiple routes of administration (oral, IV, IM) make them foundational for rapid therapy, prophylaxis, and prolonged field care.
Technical Challenges
Antimicrobial resistance (AMR) and biofilm-associated infections reduce efficacy of standard antibiotics in wound and soft-tissue injuries.
Pharmacokinetic variability in shock, hypovolemia, and polytrauma complicates dosing and therapeutic windows.
Supply-chain, cold-chain, and stability constraints limit availability of liquid biologics in austere environments.
Rapid onset needs (e.g., hemorrhage, sepsis, inhalational exposures) require fast-acting agents with predictable delivery.
Emerging Opportunities
Stable, heat-tolerant formulations that maintain potency without refrigeration for extended field deployment.
Orally bioavailable or easily administered depot/IM versions of critical drugs for prolonged and delayed evacuation scenarios.
Small molecules with novel mechanisms to overcome AMR and reduce reliance on broad-spectrum antibiotics.
Point-of-care pharmacology guidance (PK/PD-informed dosing tools) adapted to injured, hypoperfused patients.
Current and Emerging Technologies in Small Molecule Drugs
Rational drug design & structure‑based screening
Structure-guided medicinal chemistry and high-throughput screening accelerate discovery of target-selective small molecules for pathogens, coagulation pathways, inflammatory mediators, and pain receptors relevant to combat casualties.
Formulation science for stability and field use
Lyophilized, thermostable, oral solid-dosage and depot injectable formulations extend shelf-life and enable forward staging without cold-chain logistics, critical for austere and prolonged-field-care scenarios.
Rapid medicinal countermeasures and repurposing
Adaptive screening and clinical repurposing pipelines prioritize existing small molecules for emergent infectious threats, chemical exposures, and organ-specific insults to shorten time-to-deployment.
Pharmacokinetic/pharmacodynamic modeling and point-of-care dosing
Advanced PK/PD models, microsampling, and decision-support tools allow dose adjustments in shock, burn, or renal impairment to maintain therapeutic exposure in unpredictable field physiology.
Novel chemistries to counter resistance
Next-generation small molecules target resistance mechanisms, inhibit biofilm formation, or act as adjuvants to restore antibiotic susceptibility in combat-relevant pathogens.
Importance to Military Medicine
Rapid frontline therapy
Fast-acting small molecules provide immediate control of infection, pain, and physiologic derangements during delayed evacuation or prolonged field care.
Austere operational readiness
Thermostable, compact drug formulations reduce logistical burden and maintain force readiness across distributed and resource-limited environments.
Versatility across casualty types
Small molecules address a broad range of combat injuries—infectious complications, hemorrhage-related sepsis, traumatic pain and inflammation—supporting damage-control and reconstructive phases.
Manufacturing and surge capacity
Scalable chemical synthesis enables rapid production ramp-up for emergent threats and large-scale prophylaxis or treatment needs.
Alignment with the MTEC Mission
Accelerates transition of military-relevant therapeutics into the field, matching MTEC’s mission to reduce time-to-use for Warfighter health technologies.
Supports cross‑portfolio integration (trauma, infectious disease, prolonged care) by providing pharmacologic tools that complement devices and diagnostics.
Enables dual-use outcomes that benefit civilian public health while prioritizing military readiness and austere-operational requirements.
Leverages MTEC’s consortium model to connect government priorities with industry and academia for accelerated development and operational testing.
Dual-Use (Military + Civilian) Applications
Dual-use therapeutics increase civilian biodefense and outbreak response capacity while meeting military requirements for rapid deployment and shelf-stable storage.
Repurposed small molecules provide accelerated clinical pathways during public health emergencies and battlefield exposures where time is critical.
Commercial manufacturing infrastructure supports military surge needs and reciprocally improves civilian access to essential medicines.
Collaborative R&D delivers technologies that transition between civilian hospitals and forward military medical units with minimal modification.
Explore MTEC Members with Small Molecule Drugs Capabilities
MTEC members bring medicinal chemistry, formulation science, PK/PD modeling, and operational testing expertise that uniquely accelerate small-molecule solutions from bench to battlefield. Explore member profiles to find partners with GMP manufacturing, clinical trial experience in trauma and infectious disease, and capabilities in stability testing and field evaluation.
94 Members with Small Molecule Drugs capabilities.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.
Vindhya Data Science is a women-owned small business headquartered in North Carolina, USA, with a presence in RTP and Boston. We specialize in bioinformatics, genomics, artificial intelligence, and data engineering, cheminformatics, evidence-based medicine, epidemiology and related disciplines. Vindhya partners with federal government agencies, leading academic medical centers, and pharma/biotech organizations to transform large datasets into informed decisions using advanced data science technologies. With over 100 years of combined experience, 150+ publications, and 73+ successful projects, Vindhya is committed to delivering impactful solutions in the life sciences sector.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Kane Biotech is a Canadian-based biotechnology company focused on the research, development, and commercialization of products that prevent and remove microbial biofilms. Established in 2001, the company aims to improve human and animal welfare through innovative solutions to biofilm-related challenges and antimicrobial resistance. With a strong portfolio of 54 patents and patents pending, Kane Biotech is recognized as a leader in biofilm research and technology, and is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTC Markets under the symbol 'KNBIF'.
Innospera Pharma is a privately held biotechnology company based in Montreal, focused on developing small-molecule modulators targeting G-protein coupled receptors (GPCRs), particularly GPR84 and GPR40, for the treatment of chronic, fibrotic, inflammatory, and metabolic diseases. Its pipeline includes next-generation lipid-mimetic compounds designed to address unmet medical needs, with lead candidates intended for conditions such as idiopathic pulmonary fibrosis and various cardiometabolic disorders. The company leverages extensive scientific expertise and preclinical data and is supported by investors such as Investissement Québec, Seido Capital, and Anges Québec.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.
Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.